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ABSTRACT OF THESIS

ESCALATION AND REINSTATEMENT OF FENTANYL SELF-ADMINISTRATION
IN MALE AND FEMALE RATS
Escalation of intake and craving are two DSM-5 hallmark symptoms of opioid use
disorder (OUD). Objectives: This study determined if escalation measured by long access
(LgA) self-administration and craving measured by reinstatement are related. Adult male
and female Sprague-Dawley rats were trained to self-administer (SA) fentanyl across 7
daily 1-h sessions, followed by 21 SA sessions of either 1- or 6-h duration. Assignment to
short access (ShA) and long access (LgA) groups was randomly determined for both males
and females. Following 14 1-h extinction sessions, Experiment 1 assessed reinstatement
induced by either fentanyl (10 or 30 µg/kg) or yohimbine (1 or 2 mg/kg), while Experiment
2 assessed reinstatement induced by a drug-associated cue light. Females acquired fentanyl
SA faster than males and self-administered more than males throughout escalation. In
extinction, compared to ShA rats, LgA rats initially responded less and showed less decay
of responding across sessions. A fentanyl prime induced reinstatement, with LgA rats
reinstating more than ShA rats at the 30 µg/kg dose; this effect of was specific to males.
Yohimbine (1 mg/kg) also induced reinstatement, but there was no effect of access group
or sex. With cue-induced reinstatement, LgA females responded less than LgA males and
ShA females; the reduced fentanyl seeking to a cue in LgA females may reflect a general
decrease in behavior, as this group also showed suppressed locomotor activity in a different
context. Among the different reinstatement tests assessed, escalation of fentanyl SA in the
LgA group increased only drug-primed reinstatement and only in males, suggesting a
limited relationship between escalation of intake and craving (reinstatement) for OUD.
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CHAPTER 1. INTRODUCTION
1.1

Opioids
Opioids are a category of chemically related substances that bind to and activate

opioid receptors, primarily in the central and peripheral nervous systems, to produce a
physiological effect (Merriam-Webster’s Collegiate Dictionary, n.d.).
1.1.1

Classes of Opioids
There are four classes of opioids: (1) endogenous, (2) opium alkaloids, (3) semi-

synthetic, and (4) fully synthetic. Endogenous opioids are neuropeptides naturally
produced in the body, primarily in the central nervous system. Some examples include
enkephalins, nociceptins, endorphins, and dynorphins (Pathan & Williams, 2012), which
are derivates of pro-enkephalin, pro-opiomelanocortin (POMC), and pro-dynorphin
(McNally & Akil, 2002). These precursor proteins are broken down into smaller peptides,
which are further modified in post-translational processes and produces the endogenous
opioid neuropeptides mentioned above (Froehlich, 1997). These endogenous opioids then
play vital roles in multiple physiological functions, including stress, pain, respiration,
gastrointestinal transit, immune, and endocrine regulation (Bodnar, 2013). Other opioid
classes originate exogenously.
Opium alkaloids, such as morphine, codeine, and thebaine, are naturally derived
from Papaver somniferum, the opium poppy plant. Opium alkaloids obtained from
cultivating the opium poppy plant were utilized in multiple ancient cultures for food
production, rituals, and medicine. Around the eighth century, Arab traders transported
opium to China and India. Opium use quickly spread to the remainder of Asia and Europe
1

around the tenth and thirteenth centuries. Manuscripts describing opium addiction in Egypt,
Germany, England, and Turkey were found dated as early as the sixteenth century.
Although China tried to subdue opium trade, British and French forces pressed China to
appeal trade bans in the first and second opium wars, which ultimately led to more
widespread opioid use (Brownstein, 1993). The modern era of opioids began in 1806 when
Friedrich Sertürner isolated pure morphine from opium and boomed with the invention of
the hypodermic syringe in 1853 for medical use as an analgesic for post-surgical pain
(Blakemore & White, 2002). These new innovations further promoted opioid abuse.
Soon, individuals began to search for less addictive alternatives to morphine and
opium, and created the first semi-synthetic opioid, heroin, in 1898 (Brownstein, 1993).
Semi-synthetic opioids, like heroin, hydromorphone, hydrocodone, and oxycodone, are all
hybrids created chemically by altering natural opiates (Pathan & Williams, 2012). Shortly
afterwards, fully synthetic opioids such as meperidine, methadone, and fentanyl were
synthesized in 1939, 1946, and 1960 respectively, for the same reason (Brownstein, 1993;
Stanley, 1992). In contrast to semi-synthetic opioids, fully synthetic opioids are entirely
chemically manufactured (Pathan & Williams, 2012).
1.1.2

Receptors
All opioids act by binding to and activating G-protein coupled (GPCRs) opioid

receptors. There are three primary opioid receptor subtypes that bind opioid ligands: δ
receptors, μ receptors, and κ receptors. These receptors are endogenously activated by
enkephalins, endorphins, and dynorphins respectively, but may also be activated by
exogenous opioids in the other opioid classes (Shang & Filizola, 2015). A fourth opioidlike receptor, the nociception receptor, is related to these three opioid receptor subtypes,
2

but shows little affinity for endogenous opioid peptides other than nociceptin (Pradhan et
al., 2011; Butour et al., 1997). All opioid receptors are either Gi or Go protein coupled
(Wolf, 2012).
Although these receptors differ slightly in function, they produce a comparable
cellular response downstream following the binding of an opioid agonist. Each opioid
receptor exchanges its α subunit guanosine diphosphate molecule (GDP) for a guanosine
triphosphate (GTP). Following this exchange, the α subunit and GTP molecule separates
from the beta gamma complex, allowing both structures to interact with proteins and inhibit
adenylyl cyclase. This process often results in a decrease in cyclic adenosine
monophosphate (cAMP) production, activation of potassium ion channels, inactivation of
calcium ion channels, and hyperpolarization of the cell (Harrison et al., 1998; Corbett et
al., 2006). In some cases, though, opioid receptor activation can result in heightened
calcium influx (Pathan & Williams, 2012). These receptors also interact with arrestins that
are associated with GCPR endocytosis, desensitization, and kinase signaling (Bull et al.,
2017).
Although δ receptor, μ receptor, and κ receptor expression overlaps in most
structures, some brain areas express more of one subtype over others. The δ opioid receptor
subtype is heavily expressed in the neocortex, medial amygdala, and various olfactoryassociated brain areas. They are more selectively represented in the pontine nucleus of the
cerebellum. The κ opioid subtype is more abundant in the basal anterior forebrain but is
the sole opioid receptor subtype expressed in multiple stress-associated areas such as the
paraventricular nucleus, central amygdala, and pituitary gland. The μ opioid receptor
subtype is more densely represented in the amygdala (excluding the central amygdala),
3

thalamus, mesencephalon, and brain stem, but is also selectively expressed certain thalamic
nuclei (Le Merrer et al., 2009). These three receptor subtypes are also expressed in
peripheral areas such as the gastrointestinal tract, immune system, and heart, but to a lesser
extent than in the central nervous system (Stein et al., 2003).
1.1.3

Mechanism of Action
In response to endogenous or exogenous opioids, opioid receptors produce an

antinociceptive effect and alter how pain is perceived. Major portions of the descending
pain pathway, including the dorsal horn of the spinal cord, rostral ventromedial medulla
(RVM), and periaqueductal gray (PAG), express μ opioid receptors. Opioid receptors in
this pathway regulate peripheral opioid-associated antinociception. Opioid binding to μ
opioid receptors on GABAergic neurons in the PAG disinhibits RVM-projecting PAG
neurons (Lueptow et al., 2018). This results in the excitation of dorsal horn projecting
enkephalin and 5-hydroxytryptamine (5-HT) neurons (Pathan & Williams, 2012), which is
associated with inhibition of ascending pain signals, immense pain relief, and loss of
sensation.
Opioids are also known to induce respiratory depression, which may be mediated by
μ opioid receptors in certain brain stem locations (Dahan et al., 2018). The pre-Bötzinger
complex in the medulla regulates respiratory rhythm and is critical to opioid-induced
respiratory depression (Boom et al., 2012). The pre-Bötzinger complex also shows areas
with μ opioid, neurokinin, and somatostatin receptor overlap (Ramirez, 2010). Evidence
indicates that opioids target μ opioid receptors on neurokinin-1 receptor expressing neurons
in the pre-Bötzinger complex. The inhibition of these neurons, via opioid receptor binding,
is thought to cause the decreased respiratory rate associated with opioid administration.
4

This area in the pre-Bötzinger complex expressing neurokinin-1 receptors appears more
sensitive to the inhibitory effects of opioids and may be the primary respiratory mediating
area associated with opioid-induced respiratory depression (Montandon et al., 2011). The
reduction in respiratory rate and decrease in sensation combination resulting from opioid
use produces a relaxing effect and may lead to unconsciousness, and ultimately to death.
The μ opioid receptor subtype is also associated with the reward pathway and is the
primary target underlying opioid abuse. Morphine and other opioids of abuse bind to
presynaptic μ opioid receptors on GABAergic ventral tegmental area (VTA) neurons. This
results in a reduction of inhibitory tone on dopaminergic neurons targeting the striatum.
Consequently, dopamine (DA) release in the striatum increases, which is associated with
the rewarding, but not reinforcing, effects of opioids of abuse (Fields & Margolis, 2015).
Evidence indicates that knockout of the μ opioid receptor gene in mice prevents morphineinduced analgesia, decreases the rewarding effect of morphine, and lessens morphine
withdrawal (Matthes et al., 1996). Also, μ opioid receptors in the amygdala may mediate
reward-associated cue processing. Reward-directed behavior following a rewardpredictive cue decreases after μ opioid receptor inactivation but does not affect reward
motivated behavior alone. This suggests that the role of μ opioid receptors in the amygdala
may be vital to reward-associated cue recall for motivated behavior (Lichtenberg &
Wassum, 2017).
Less is known about δ receptors and κ receptors in terms of behavioral
pharmacology. While activation of κ receptors tends to produce aversive effects, there is
evidence that the receptor may be associated with the stress response and depression.
Similarly, δ receptors may be involved in stress and depression, but additionally regulate
5

pain and reward (Pradhan et al., 2011). This combination of effects produced by μ, δ, κ and
opioid receptor binding could produce an overdose, where individuals become unconscious
with little to respiration and the risk of death is high (World Health Organization, 2018).
1.1.4

Abuse Liability and Risk Factors for Abuse
Considering the role of μ opioid receptors in the reward system, many opioids

express high abuse liability. The rate of abuse for μ opioid receptor ligands, however, is
dependent upon pharmacodynamics and pharmacokinetics. Pharmacokinetics determine
how well the opioid ligand reaches and binds to the μ opioid receptor. The route of opioid
administration can alter how well the administered opioid is absorbed into the bloodstream.
Opioid bioavailability may decrease following some methods of opioid administration,
such as oral and sublingual administration, by undergoing first pass liver metabolism.
Other methods, such as intravenous injection, avoid first pass liver metabolism and allow
opioids to reach the brain faster in higher concentrations (Stahl, 2008). Once opioids reach
the brain via blood supply, they must cross the blood brain barrier (BBB). A lipophilic
ligand with a low molecular weight may pass through the BBB using lipid-mediated free
diffusion; however, highly lipophilic ligands are more likely to sequester in peripheral
tissues, decreasing bioavailability (Pardridge, 2015; Banks, 2009). Heroin, for example,
has a greater lipid solubility than morphine, which allows it to cross the BBB more easily.
Although heroin is broken down into morphine after crossing the BBB, its ability to cross
the BBB more efficiently than morphine makes it much more potent (Rutgers, 2018). Some
opioids may be actively transported across the BBB or may utilize both passive diffusion
and active transport. Evidence suggests that fentanyl uses both methods of transport,
maximizing the amount of fentanyl crossing the BBB (Henthorn et al., 1999). Some ligands
6

may pass through the BBB using passive aqueous diffusion; however, the molecule must
have a small molecular weight (Stahl, 2008). Once an opioid ligand reaches the μ opioid
receptor, the ligand’s affinity determines how well it attracts to the receptor to bind and
exert an effect. Opioids with a higher affinity for the μ opioid receptor typically express
higher potency (Ellis et al., 2018). Fentanyl has one of the highest affinities for the μ opioid
receptor (Trescot et al., 2008) and is highly potent.
The pharmacokinetics of μ opioid receptor ligands also vastly impacts the likelihood
of opioid abuse. The efficacy of a μ opioid receptor ligand determines how well it produces
the μ opioid receptor-mediated effects mentioned above. Opioids that act as full agonists
at μ opioid receptors, such as morphine, heroin, fentanyl, and oxycodone, activate μ opioid
receptors and initiate the downstream cellular effects associated with reward. Partial
agonists, such as buprenorphine, bind to μ opioid receptors but display partial efficacy and
a lower abuse potential compared to a full agonist (University of Arkansas Medical Center,
2020). Antagonists, such as naloxone, however, block μ opioid receptors and are often
added to other opioids to decrease abuse liability (Comer et al., 2010).
The repeated administration of opioids and activation of μ opioid receptors may
produce long-term changes in receptor regulation and neurocircuitry. These neural
adaptations often manifest behaviorally as physical dependence and withdrawal in the
absence of a μ opioid receptor agonist. Opioid withdrawal signs such as nausea, diarrhea,
insomnia, autonomic hyperactivity, and piloerection are indicative of physical dependence
(Shah & Huecker, 2020) . Withdrawal following opioid self-administration is aversive and
removal of this aversive state by continued use acts as a negative reinforcer, which
perpetuates the likelihood of continued opioid abuse (Koob, 2020; Thompson et al., 2012).
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The interplay between opioid pharmacodynamics and pharmacokinetic factors heavily
influence their abuse liability.
Various environmental and biological factors contribute to the abuse liability of
opioids at the individual level. Opioids are often prescribed following surgery, so discretion
is needed when prescribing opioids as postsurgical care. Evidence suggests that a history
of substance abuse, physical disabilities, previous mental health diagnoses, untreated
psychiatric disorders and the prescription of some psychiatric medications are all predictors
of opioid abuse following surgery in adults (Burcher et al., 2018; Klimas et al., 2019). Risk
for opioid misuse is particularly higher in women with depression and men with
somatization disorder (Manchikanti et al., 2007). Also, social environmental factors that
encourage misuse similarly promote opioid abuse (McCarberg, 2015; Webster, 2017).
Other factors that contribute to opioid dependence include: unemployment, post-traumatic
stress disorder (PTSD), depression, anxiety, anti-sociality, trauma, younger age, substance
abuse treatment, and co-use of psychotropic medication, alcohol, or illicit substances
(Boscarino et al., 2010; Webster, 2017).
Genetics are another factor associated with a predisposition towards opioid abuse.
Multiple dopamine-associated genes such as those coding the dopamine D2, D3, and D4
receptor subtypes, as well as the catecholamine enzyme catechol-O-methyltransferase
(COMT), are linked to opioid abuse (Boscarino et al., 2010; Wang et al., 2019), and likely
alter how opioids function in the reward system. Likewise, polymorphisms of opioid
receptor genes and serotonin-associated mechanisms are correlated with opioid
dependence and may promote abuse (Wang et al., 2019). Alterations in how opioids are
degraded, however, may promote the adverse effects of certain opioids and decrease the
8

likelihood of abuse. Evidence indicates that individuals with a certain polymorphism of the
CYP2D6 enzyme gene may experience heightened adverse effects after administering
codeine or tramadol (Haufroid & Hantson, 2015). These are all potential factors that can
influence the abuse liability of opioids at the societal and individual levels.
Opioids and other controlled substances are categorized into five schedules that
reflect the potential for abuse, potential to develop dependence, and for potential medical
use. These schedules are organized by the Drug Enforcement Agency (DEA) in the United
States so that substances with a higher abuse liability fall closer to schedule I and
substances with little to no abuse liability fall closer to schedule V. Most opioids are
classified as schedule I or II, considering their high rate of abuse. Schedule I opioids, such
as heroin, are considered to have no accepted medical use, a high abuse potential, and
increased likelihood to develop dependence; whereas, schedule II opioids, such as
morphine, may have a high abuse potential and increased likelihood to produce
dependence, but show some medicinal use (DEA, 2020).
1.1.5

Fentanyl
Fentanyl is a schedule II, synthetic opioid with high abuse liability. Fentanyl’s

heightened lipid solubility increases its potency by maximizing its ability to cross the BBB.
Once inside the brain, fentanyl acts as a full μ opioid receptor agonist and produces effects
common to opioids such as respiratory depression, sedation, analgesia, and a feeling of
reward. Considering fentanyl’s high potency, a small amount of drug may produce a rapid
rewarding effect; whereas, a large amount of a less potent opioid, such as morphine, may
be necessary to produce an equivalent but potentially slower acting effect (DEA, 2019). In
humans, the i.v. administration of fentanyl citrate distributes within 1.7 minutes and the
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elimination half-life ranges from 2-4 hours (Akorn Inc., 2017; El-Karamany, 2017);
however, the elimination half-life of fentanyl varies from 2-27 hours dependent upon the
route of administration and rate of absorption (El-Karamany, 2017). Cytochrome P450
(CYP450) metabolizes 99% of fentanyl into the inactive metabolite norfentanyl. The
remaining 1% of fentanyl is metabolized to other inactive metabolites such as
hydroxyfentanyl and despropionylfentanyl (DePriest et al., 2015; Smith, 2009). These
properties of fentanyl inflate its abuse liability and likelihood of overdose following use.
Despite the high abuse potential of fentanyl, it is utilized medically as a reliever of
severe pain and is consequently categorized as a schedule II substance (DEA, 2020).
Prescription or casual illicit fentanyl use though, may quickly progress to fentanyl
dependence and lead to overdose. While fentanyl alone is often abused, it is often
combined, knowingly or unknowingly, with heroin or cocaine to produce a heightened
euphoric effect, further promoting opioid associated overdose. Over 31,000 opioid
associated overdose deaths were linked to synthetic opioids in 2018, which appeared to be
a result of a rise in illicit fentanyl use (CDC, 2020). This places fentanyl use at the forefront
of the opioid epidemic.

1.2

Opioid Use Disorder
Opioid use disorder (OUD) became a national concern when the rise in prescription

opioid use resulted in a vast misuse of opioids and an ‘epidemic’ of opioid-associated
overdose deaths. The introduction of illicit heroin and fentanyl further exacerbated the
epidemic. Although OUD has become a rising issue, there are still some gray areas in the
understanding of OUD and how certain symptoms may be related.
10

1.2.1

The Epidemic
Opioid overdose deaths have been increasing exponentially over the past decade.

In 2017 alone there were an estimated 47,600 opioid-related overdose deaths in the United
States, a 12% increase over the previous year (Scholl et al, 2019). Between 1999 and 2018,
an estimated 450,000 people died of an opioid-associated overdose. The CDC reports there
were three distinct waves of opioid use that led the United States to the current state in
opioid overdose deaths (CDC, 2020). The first wave of the epidemic occurred following
the increase in opioid prescriptions for pain relief in the 1990’s. As the number of opioid
prescriptions continued to increase, the number of opioid overdose deaths associated with
prescription opioids continued to increase (CDC, 2011). In 2010, as prescription opioid
overdose deaths began to plateau, there was there another wave of opioid overdose death
associated with heroin (Rudd et al., 2014).
The third wave of opioid overdose deaths began more recently with the surge in
synthetic opioid use. Of all opioid-associated overdose deaths in 2017, 59.8% were caused
by a synthetic opioid other than methadone, representing a 45.2% increase from 2016 to
2017 (Scholl et al., 2019). Beginning in 2013, illicit fentanyl became increasingly available
(CDC, 2020), and use is rising significantly, especially in areas where more preventatives
for prescription opioid use are in place (Fischer et al., 2020). Fentanyl is 100 times more
potent than morphine, easily manufactured illicitly, and is frequently mixed with other
substances of abuse, such as cocaine and heroin (CDC, 2019; Carroll et al., 2017; Klar et
al., 2016). Multiple synthetic opioid-associated overdose deaths involved other substances
which may be a result of drug mixing (CDC, 2020). These factors may allow users to easily
obtain lethal doses and encourage the use of synthetic opioids, which may lead to
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worsening symptoms of opioid use disorder (OUD) and increase the likelihood of
overdose.
1.2.2

DSM-5 Criteria
The DSM-5 defines opioid use disorder (OUD) as a chronic relapsing substance use

disorder where intake escalates in both amount and duration, and users experience opioid
craving, which often occurs during periods of abstinence and precipitates relapse
(American Psychiatric Association, 2013). Considering the highly rewarding, positive
reinforcing effect associated with use of opioids like fentanyl, misuse may rapidly develop
into OUD and ultimately end in overdose. In fact, physical dependence may occur within
4-8 weeks (Sharma et al., 2016). The DSM-5 is used to establish common guideline for
clinician diagnoses and describes OUD as a problematic pattern of behavior associated
with opioid use, which may result in distress or conflict. There are eleven criteria listed in
the DSM-5 that are associated with OUD and individuals must meet at least two of the
descriptions within a 12-month period to fit an OUD diagnosis. Individuals with OUD may
express an inability to fulfil work, school, or home responsibilities, may not participate in
activities, and may use a vast amount of time to obtain, use, or recover from opioid use.
Continuing opioid use despite frequent social, physical, or psychological problems and
using them in potentially harmful situations are also indicators of OUD. Following an
absence of opioid use, individuals with OUD may experience symptoms of withdrawal and
use opioids to alleviate withdrawal symptoms (APA, 2013).
The current study outlined in this thesis places emphasis on the two key criteria
mentioned in the DSM-5: (1) those with OUD may use opioids in large amounts and over
a lengthy period, with little ability to control opioid intake, and (2) following a period of
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abstinence from opioids, users may experience a craving or desire, which promotes a return
to drug-seeking (APA, 2013). Specifically, this preclinical study sought to determine if
there is a relationship between these two criteria by assessing the escalation of intake with
long-access self-administration sessions to model escalation (criterion 1) and by assessing
reinstatement of fentanyl seeking following a period of extinction to model craving
(criterion 2).
1.2.3

Escalation of Intake and Craving
While escalation of intake and relapse are often considered to be separate

characteristics of OUD that may involve dissociable mechanisms, evidence suggests that
intake amount may influence the propensity to relapse. While escalation and relapse have
previously been considered unrelated and separate characteristics of OUD, evidence
suggests that greater intake leads to increased risk of relapse (Smyth et al., 2010; Chalana
et al., 2016). Similarly, a history of compulsive use and signs of dependence are associated
with increased likelihood of relapse (Grau-Lopes et al., 2012). The level of use predicts
success in outpatient treatment, where lower levels of lifetime and past-month intake
correspond to improved outcomes for patients receiving buprenorphine maintenance
treatment (Woodcock et al., 2015). There is also at least one preclinical study indicating
that escalation of cocaine intake leads to increased drug-primed reinstatement in rats
(Mantsch et al. 2004), suggesting that the mechanisms underlying escalation and
reinstatement may overlap, at least in part. Thus, when examining relapse-like behavior in
animal models it is critical to account for the dysregulated pattern of intake that is typical
of humans with OUD.
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1.3

Animal Models of Escalation
There are a variety of animal models that simulate the escalation of intake;

however, most current models utilize cocaine or other stimulant drugs. The escalation of
cocaine intake can be achieved in rodents following 2-h self-administration sessions;
however, extending the session length to 6-h results in greater escalated intake (Mandt et
al., 2015). Rodents show poorer performance on a rodent equivalent of the Iowa Gambling
Task 24-h following the escalation of cocaine intake and continue to perform worse one
week later, suggesting that the escalation of cocaine intake may produce lasting changes
and influence future behavior (Cocker et al., 2020). Escalated cocaine intake also occurs
following intermittent access and may be more efficient in enhancing the incentive
motivation for cocaine (Allain et al., 2018).
Fewer studies have examined the escalation of opioid intake. The escalation of
opioid intake can be achieved with various opioids in rodent models using long-access selfadministration, where animals self-administer for session lengths of 6-h or longer (Wade
et al., 2015). This pattern of escalated opioid intake seems to perpetuate withdrawal after
drug removal. C57BL/6J mice escalate their intake of i.v. heroin when given 6-h access to
self-administer heroin and show heightened symptoms of withdrawal after escalation
(Towers et al., 2019). Rats given access to vaporized sufentanil for 12-h per day similarly
increase their intake across daily self-administration sessions and express heightened
naloxone-precipitated signs of withdrawal compared to rats maintained on 1-h daily
sessions (Vendruscolo et al., 2018). This demonstrates that there is a significant amount of
progress in modeling the escalation of opioid intake and other potentially associated OUD
symptoms; however, the impact of opioid escalation on relapse in animal models is largely
unknown.
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1.4

Animal Models of Reinstatement
Relapse is modeled in laboratory animals using various paradigms designed to

promote a return to drug-seeking behavior. Often, these procedures involve the use of
rodents with indwelling venous catheters trained to self-administer a substance or rodents
that have undergone conditioned place preference (CPP) for a specific drug of abuse.
Following a period of extinction training, forced abstinence or voluntary abstinence, these
methods may include the reintroduction of a drug or drug-associated cue, the introduction
of a stressor, or administration of a different pharmacological substance other than the one
previously self-administered. During this reinstatement period, the return to drug-seeking
behavior is measured (Beardsley & Shelton, 2012).
1.4.1

Drug-induced Reinstatement
The administration of an opioid after opioid self-administration or conditioned

place preference (CPP) and extinction often results in reinstatement (Reiner et al., 2019).
Morphine administration during CPP induces a preference for a single compartment in
comparison to other compartments that can be extinguished and observed again when
morphine is reintroduced (Khaleghzadeh-Ahangar & Haghparast, 2015). The
administration of heroin after extinction from heroin self-administration initiates a return
to heroin-seeking. Also, rats exposed to both heroin and cocaine during self-administration
will show drug-specific lever responding and reinstatement after the reintroduction of
heroin or cocaine after extinction (Leri & Stewart, 2001). The intracerebral injection of
morphine into the VTA similarly produces reinstatement of morphine-seeking (Stewart,
1984), suggesting that lasting neural changes may occur following the self-administration
of morphine. Heroin-induced reinstatement involves the μ opioid receptor, the dopamine
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D1 and D2 receptors, and perhaps cannabinoid receptors (Reiner et al., 2019, Fattore et al.,
2011). It is likely that these reward-relevant receptors undergo changes during long-access
(6-h) self-administration of opioid intake that does not occur during short-access (1-h).
Further, drug-primed reinstatement of heroin seeking occurs in rats trained on extended (6h) access, but not in rats trained on short (1-h) access using the extinction/reinstatement
paradigm (Lenoir & Ahmed, 2007). However, it is not known if differences in short-access
(ShA) vs long-access (LgA) self-administration also occur with stress- or cue-induced
reinstatement, nor is it known if this effect generalizes to high potency opioids such as
fentanyl.
1.4.2

Stress- and Yohimbine-induced Reinstatement
The hypothalamic-pituitary-adrenal (HPA) axis plays a key role in substance abuse

and withdrawal. The HPA axis activates in response to acute administration of various
substances of abuse and during withdrawal (Kreek & Koob, 1998). In animal models, the
acute administration of alcohol (Mendelson et al., 1971), nicotine (Kirschbaum et al.,
1992), and cocaine (Heesch, 1995) all increase cortisol release through the HPA axis. The
HPA axis appears to adapt after chronic nicotine exposure by increasing basal tone,
resulting in more intense withdrawal during early abstinence (Wemm & Sinha, 2019). This
effect seems to be a result of nicotine’s ability to activate the HPA axis by inducing the
release of corticotrophin releasing factor (CRF) and norepinephrine in the paraventricular
nucleus (PVN; Fu et al., 1997; Matta et al., 1990; Okada et al., 2003). Similarly, opioids
appear to alter the HPA axis via changes in CRF regulation. Former heroin users on
methadone maintenance express adrenocorticotropic hormone (ACTH) plasma levels
equal to normal male volunteers after placebo but express significantly higher ACTH
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plasma levels after the administration of high-dose human CRF (Schluger et al., 2003). In
rodents, i.c.v. infusion of a CRF2R antagonist during morphine withdrawal produces a
decrease in somatic naloxone-induced withdrawal symptoms (Navarro-Zaragoza et al.,
2011). In addition, i.c.v. injection of CRF augments reinstatement to heroin seeking and
pre-treatment with a CRF antagonist attenuates footshock stress-induced reinstatement
(Shaham et al., 1997). The changes in HPA axis and CRF regulation during opioid use
likely trigger craving and relapse following stress in rodent models of OUD.
Stress-induced reinstatement typically involves the administration of a stressor
following a period of extinction. Rats display a robust return to heroin seeking after
exposure to a brief footshock stressor (Shaham & Stewart, 1995; Shalev et al., 2000) or
after 1-day food deprivation stress (Shalev et al., 2000). However, individual biological
and behavioral factors may contribute to the propensity of stress-induced relapse to heroin
seeking (Stafford et al., 2019). This effect also appears context specific. When footshock
is performed in a drug-associated context, reinstatement to heroin seeking occurs.
However, when footshock is performed in a novel context, the effect on heroin seeking is
absent (Shalev et al., 2000). In mice, morphine CPP is reinstated after swim stress (Li et
al., 2013; Ma et al., 2007), restraint, tail pinch, and social defeat stress (Riberio Do Couto
et al., 2006). In contrast, acute food deprivation stress does not produce a reinstatement of
morphine CPP (Ma et al., 2007).
There are also various pharmacological methods used to mimic stress-induced
reinstatement of opioid seeking. This thesis study focuses on the pharmacological stressor
yohimbine, an alpha-2 adrenoceptor autoreceptor antagonist that activates the sympathetic
nervous system in humans and rodents to mimic stress and anxiety (Bremner et al., 1996a
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and b). The use of yohimbine as a pharmacological stressor has become more common
because (1) it produces a robust return to drug seeking, (2) its reinstating effects can be
blocked by CRF1 receptor antagonists, and (3) it can be used in both human and animal
models of reinstatement (Mantsch et al., 2016). Yohimbine provokes a return to alcohol
(Le et al., 1998), methamphetamine (Shepard et al., 2004), cocaine (Feltenstein & See,
2006), and nicotine seeking in rats (Feltenstein et al., 2012). Yohimbine administration
also reinstates food seeking behavior (Cifani et al., 2012). While little preclinical research
has examined the reinstating effects of yohimbine on opioid seeking, clinical studies
indicate that yohimbine produces anxiety-like symptoms and opioid seeking in opioiddependent patients on methadone maintenance (Stine et al., 2002) or buprenorphine
maintenance (Greenwald et al., 2013). This study examined the reinstating effects of
yohimbine after fentanyl escalation.
1.4.3

Cue-induced Reinstatement
In addition to context-induced reinstatement of drug seeking, cue-induced

reinstatement promotes a return to drug seeking. In cue-induced reinstatement, animals are
trained to self-administer a drug that is paired with a discrete cue (e.g., light, tone, scent).
These cues become paired with drug intake across multiple self-administration sessions.
During extinction, self-administration behavior dissipates when access to drug is removed
with the concomitant removal of discrete or discriminate cues. Reinstatement is assessed
when drug-associated cues are returned (Marchant et al., 2015; Shaham & Nair, 2010;
Reiner et al., 2019).
Exposure to a single discrete cue associated with drug taking promotes
reinstatement to heroin seeking (Lai et al., 2013, Yue et al., 2014; Galaj et al., 2015; Smith
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& Aston-Jones, 2012). This effect can be prevented by blocking certain DA receptors.
Risperidone, a D2 and 5-HT2A antagonist, and l-stepholidine, a dual D1 partial agonist
and D2 antagonist, both attenuate cue-induced reinstatement to heroin seeking (Lai et al.,
2013; Yue et al., 2014). Evidence also indicates that a D3 antagonist reduces heroin seeking
following reintroduction of a heroin-associated cue (Galaj et al., 2015). Areas in the DA
reward system, such as the NAc and prefrontal cortex (PFC), appear to regulate opioid
seeking following cue-induced reinstatement. VTA or NAc microinjection of the sodium
channel blocker tetrodotoxin prevents responding during extinction and heroin seeking
behavior during cue-induced reinstatement (Zhou et al., 2007). Likewise, temporary
inactivation of the mPFC using a muscimol and baclofen combination to block neural
activity reduces cue-induced reinstatement of heroin seeking (Rogers et al., 2008). Perhaps,
these areas undergo changes during the escalation of opioid intake, altering DA receptor
regulation and susceptibility to cue-induced relapse. Following the escalation of fentanyl
intake using intermittent access, but not long-access, male rats expressed greater cueinduced reinstatement compared to short-access (Fragale et al., 2020). Currently, no study
examines the effect of escalation on cue-induced reinstatement on fentanyl seeking in rats.
1.4.4

Limitations of Animal Models of Reinstatement
Animal models of reinstatement have been criticized for their limited ability to model

relapse in the human population (Epstein & Preston, 2003). In particular, during the
extinction period of the extinction/reinstatement model, animals are allowed to continue
responding for saline. This does not directly parallel to the human condition, where
individuals undergo self-imposed abstinence (Gardner, 2008), typically by choosing to
remain abstinent even when drug may be available or by attending a rehabilitation facility
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to promote abstinence when the drug is not readily available; in neither case does the
individual make a response for placebo. In addition, there are differences in the
reinstatement portion of the extinction/reinstatement model. Experimenters may
administer a drug prime to produce a return to drug seeking in animals, whereas humans
self-administer the drug prime that precedes a full relapse (Marlatt, 1996). Similarly, with
cue-induced reinstatement, experimenters may remove drug-associated cues during
extinction in animals, whereas these drug-associated cues are not as easily removed in
humans. For example, one study found that while handling money can trigger craving for
heroin (Epstein et al., 2009), money is typically not removed from a recovering patient’s
environment. Considering the disparity between animal models of reinstatement and the
characteristics of relapse in humans, more translational animal models of reinstatement
should be explored.
Reinstatement models using forced or voluntary abstinence have attempted to better
model the human condition by serving as analogues to human treatment in a rehabilitation
facility or the continued choice to remain abstinent. In some forced abstinence models,
instead of remaining in the drug-associated context, animals are relocated to a differing
context with no drug or drug-associated cues available (Reichel & Bevins, 2009). In
voluntary abstinence models, animals remain in the drug-taking context but are presented
with a choice between the drug and an alternative reinforcer such as palatable food or the
chance to interact with a social peer. Under these conditions, animals will voluntarily
refrain from drug taking even when drug is available (Venniro et al., 2019). Although these
models may offer more appealing animal parallels to the conditions preceding human
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relapse, the current study was conducted with the extinction/reinstatement model of relapse
because of the wealth of literature using this well-established method of reinstatement.

1.5

Sex Differences in Opioid Use Disorder
Males and females differ in performance on various assessments of OUD and show

distinct patterns of opioid use. Generally, females acquire drug taking faster, escalate intake
more rapidly, stabilize intake at higher doses, and relapse at a greater rate than males
(Becker et al., 2017). Compared to men, women are more likely to use prescription opioids
(Serdarevic et al., 2017); however, this difference in prescription opioid use may be
explained by contrasting perceptions of pain. Women with comorbid chronic pain and
opioid abuse reported heightened social and physical impairment associated with pain
(Manubay et al., 2014). Although these patterns indicate women may be more vulnerable
to opioid abuse, there is a greater incidence of abuse in the population for males (Becker
& Koob, 2016).
In rats, females acquire the self-administration of heroin faster than males (Lynch &
Carrol, 1999) and dose-dependently self-administer morphine and heroin at greater rates
than males (Cicero et al., 2003). Females show greater self-administration than males on a
FR5 schedule of reinforcement for 0.32 and 1 ug/kg/injection of fentanyl and show greater
performance on a progressive ratio (PR) schedule for 3.2 and 10 ug/kg/injection of
fentanyl. This sex effect, however, is dependent upon schedule of reinforcement and
reverses when males and females are given concurrent access to 3.2 ug/kg/injection of
fentanyl and 18% diluted Ensure® (Townsend et al., 2019). On a progressive ratio
schedule, where the number of responses required doubled with each infusion, females had
a higher FR breaking point than males for morphine (Cicero et al., 2003). Furthermore,
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female mice escalate heroin intake at a faster rate than males across daily 6-h selfadministration sessions (Towers et al., 2019). Also, while evidence indicates that females
are more vulnerable to the reinstatement of methamphetamine, cannabinoid, and cocaine
seeking (Becker & Koob, 2016), currently no study has examined the differences in males
and female reinstatement following the escalation of fentanyl intake or reinstatement of
fentanyl seeking in rats.

1.6

Purpose of Thesis
The purpose of the current study was to determine if there is a relation between

escalation of opioid intake and relapse, as this would suggest a common underlying neural
mechanism. Toward this goal, we used a preclinical model of escalated fentanyl selfadministration and reinstatement. While both escalation of opioid use and reinstatement of
opioid seeking have been modeled in rats and mice, there have been no systematic studies
to determine if there is a relation between these DSM-like characteristics of OUD. In one
study, rats given access to vaporized sufentanil in long access (12-h) sessions showed
escalated intake and expressed heightened naloxone-precipitated signs of withdrawal
compared to rats maintained on 1-h daily sessions (Vendruscolo et al. 2018); however,
propensity for relapse was not assessed. In the current study, to model escalation, we used
a long access (6-h) schedule described previously (Wade et al. 2015; Towers et al. 2019).
To model relapse, we used the extinction-reinstatement model with forced abstinence as
described previously (De Vries et al. 1998; Shalev et al., 2002; Stairs et al. 2006).
Reinstatement was assessed by either a drug prime or a pharmacological stressor
(yohimbine), as well as by a fentanyl-associated cue.
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The second purpose of the current study was to determine if sex differences exist
in the relation between escalation and relapse with fentanyl self-administration. In both
humans and rats, escalation of drug intake and reinstatement of drug seeking are generally
higher in females than in males (Becker, 2016), although much of this work has been
conducted with stimulants. In the case of opioids, one study found that female C57BL/6J
mice escalate heroin intake with long access (6-h) sessions more than male mice, at least
when a low unit dose (30 µg/kg) is used (Towers et al. 2019). Based on this finding, we
hypothesized that female rats would show greater escalation of fentanyl intake and greater
reinstatement of fentanyl seeking compared to males.
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CHAPTER 2. METHODS
2.1

Animals
Male (n = 34) and female (n = 37) Sprague-Dawley rats from Envigo Laboratories

(Indianapolis, IN) were delivered at 8-9 weeks of age and individually housed in a
humidity- and temperature-controlled colony room maintained on a 12-h light/dark cycle
(lights on at 0700-h). All animals had access to food and water ad libitum throughout the
experiment. All rats were acquired and tested in cohorts of 12 or 24. All procedures were
performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use Committee (University of
Kentucky).

2.2

Drugs
Fentanyl HCl was acquired from the National Institute on Drug Abuse (NIDA Drug

Supply Program, Rockville, MD) was dissolved in 0.9% bacteriostatic saline to make the
doses used in the study for self-administration (2.5 µg/kg per 0.1 ml infusion volume) or
fentanyl-induced reinstatement (15 or 30 µg/kg delivered via subcutaneous [s.c.] injection).
The α2 adrenergic antagonist yohimbine HCl (Sigma-Aldrich, St. Louis, MO) was
dissolved in sterile water to prepare the two yohimbine-induced reinstatement doses (1 or
2 mg/kg delivered via intraperitoneal [i.p.] injection). Yohimbine solutions were mixed the
day prior to reinstatement and stored at 4ºC under aluminum foil until needed. All doses
were based on salt weight.
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2.3

Surgical Procedures
All rats were implanted with chronic indwelling jugular catheters with the port

secured to the head using dental acrylic, as described previously (Weiss et al. 2018). For 5
days after surgery, catheters were flushed daily using antibiotic gentamycin solution (0.2
ml), and a post-flush solution (0.2 ml; consisting of gentamycin, heparin, and saline). Rats
received 2-4 additional recovery days, where their catheters were flushed with 0.2 ml postflush solution daily.

2.4

Operant Conditioning Chambers
Operant conditioning chambers (MED-Associates, St. Albans, VT) were used and

controlled using computers equipped with MED-PC software. Chambers were enclosed in
sound-attenuating cabinets with exhaust fans, and were equipped with two levers, two cue
lights, a food receptacle, and house light. Levers were located on both sides of one wall
and cue lights were mounted above each lever. The food receptacle was positioned between
both levers. A house light was located in the upper middle portion of the opposite wall.
Syringe pumps outside the sound-attenuating cabinet connected the catheters to a leash
inside the operant chamber that moved freely via a swivel connection. During autoshaping
and acquisition, fentanyl was delivered in 10 ml syringes at an infusion rate of 0.1 ml per
5.9 sec. During the escalation phase, 20 ml syringes were used and fentanyl was delivered
at an infusion rate of 0.1 ml per 3.4 sec. Syringes were changed as needed during the
escalation sessions to avoid syringe emptying.

25

2.5

Autoshaping and Acquisition
Rats were trained to self-administer fentanyl using an autoshaping procedure for 7

consecutive days. Each day consisted of a 1-h autoshaping session, a 2-h rest in the home
cage, and a 1-h operant session. During the autoshaping session, rats were given 5 noncontingent infusions on a 6-min random time schedule across a 35-min period. For each
infusion, the active lever would extend for 15-sec and then would retract concomitant with
an infusion and illumination of both cue lights for 20-sec; if the rat pressed the lever during
the 15-sec lever extension, the lever was retracted and followed immediately by an infusion
and cue light illumination. The active lever was counterbalanced across rats. Following
delivery of the 5 infusions, the remaining 25-min of the autoshaping session was spent with
both levers retracted. The house light was turned on throughout the autoshaping session.
Immediately following each autoshaping session, all rats were placed in their home cage
(with ad libitum food and water) for 2-h before returning to the operant chambers for a 1h operant acquisition session. On this operant session, both the active and inactive levers
were continually available, and rats self-administered on a FR1 schedule; the active lever
was the same one used during the autoshaping session. Each infusion was paired with 20sec illumination of both cue lights and a time-out period, during which responses were
recorded but no infusion was delivered. The house light was turned off throughout the
operant acquisition session.

2.6

Escalation

After 7 days of acquisition, rats were divided randomly into short access (ShA; n= 16
males and n= 17 females) or long access (LgA; n= 16 males and n= 18 females) selfadministration groups. For the next 21 daily self-administration sessions, the ShA access
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group was maintained on 1-h sessions, while the LgA group had the session length
increased to 6-h. All procedures were the same as described for initial acquisition, except
that the autoshaping phase was omitted and session length was changed for LgA rats.
During escalation, some rats began to engage in self-injurious behaviors (digit
biting and aggressive grooming). These behaviors were redirected with aspen chew blocks
(large, 2 x 1.5 x 1.5 inch: Lomir Biomedical Inc., Malone, NY) placed in the home cage
and operant chambers at the start of escalation. Wounds were treated using hibiclens
antimicrobial skin liquid soap, 0.9% bacteriostatic saline, and triple antibiotic ointment
after sessions. Areas with persistent wounding were swabbed with a metronidazole and
New Skin liquid bandage mixture before, during, and/or after the session as needed.

2.7

Estrus Cycle Testing
Immediately prior to each reinstatement session, females received vaginal swabs

for estrus cycle testing and males were prodded with swabs to simulate estrus cycle testing.
Each female was swabbed twice, once to clean the area of previous dead cells, and the
second to collect vaginal wall cells for estrus cycle examination. Following vaginal cell
collection, swabs were immediately rolled onto slides and examined under light
microscope on the same day.

2.8

Experiment 1: Fentanyl- and Yohimbine-induced Reinstatement
Three cohorts of rats (total n= 8 ShA males, n= 8 ShA females, n= 8 LgA males,

n= 8 LgA females) were used to examine both fentanyl- and yohimbine-induced
reinstatement. For both ShA and LgA groups, rats underwent 14 1-h extinction sessions,
which were identical to the acquisition sessions, except that fentanyl infusions were
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omitted. On these sessions, rats were not connected to the metal leash. Reinstatement
sessions followed the same format as extinction training, except that rats received one of 5
treatments before the session: (1) 1 mg/kg yohimbine + vehicle; (2) 2 mg/kg yohimbine +
vehicle; (3) vehicle + 10 µg/kg fentanyl; (4) vehicle + 20 µg/kg fentanyl; or (5) vehicle +
vehicle. On each of these reinstatement tests, rats received two injections, with the first
injection being yohimbine or water vehicle (i.p.) and the second injection being fentanyl
or saline vehicle (s.c.). Injections were separated by 30 min and rats were placed into the
operant conditioning chambers immediately after the second injection. The order of these
test treatments was counterbalanced such that all rats received each treatment combination
in a counterbalanced order across the 5 reinstatement sessions. Each test session was
separated by 5 maintenance extinction sessions (no injections).

2.9

Experiment 2: Cue-induced Reinstatement and Locomotor Activity
Two cohorts (total n= 8 ShA males, n= 9 ShA females, n= 7 LgA males, n= 9 LgA

females) were used to examine cue-induced reinstatement. For both ShA and LgA groups,
rats underwent 14 1-h extinction sessions, which were identical to the acquisition sessions,
except that fentanyl infusions, cue light illuminations and leash attachments were omitted.
Cue-induced reinstatement was assessed on the day after the final extinction session.
During this 1-h reinstatement session, active lever presses resulted in illumination of both
cue lights and activation of the syringe pump, but fentanyl was not delivered.
Twenty-four hours after the single cue-induced reinstatement session, each rat was
placed into a novel automated activity monitor (Versamax Legacy Open Field activity box,
Omnitech Electronics, Columbus, OH) and total distance travelled was measured for 1-h.
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2.10

Statistical Analyses
Analyses were performed with SAS version 9.4. Multilevel modeling (MLM)

procedures were used to assess acquisition, escalation, extinction, and reinstatement. Initial
analyses determined whether behavior differed across cohorts. Cohort 5 was the only
cohort that differed from other cohorts, thus membership in this cohort was controlled in
appropriate models. The general form of the models of acquisition, escalation, and
extinction was for lever presses to be modeled as a function of time (session number).
Models for extinction data differed in that they took the form of a power model (log of
lever pressing predicted by log of time). The general form of the models for reinstatement
was for lever presses to be modeled as a function of drug group (vehicle, fentanyl dose, or
yohimbine dose) or cue condition, with vehicle or last session of extinction as the reference
group, respectively.
A standard model taxonomy was followed (Singer & Willett 2003), starting with
an unconditional means model (UMM), followed by an unconditional growth model
(UGM), and subsequent models including variables such as drug condition, access group
(ShA or LgA), lever type (active or inactive), sex, or interactions between these variables
as predictors of initial status and change in lever pressing over time. To determine the
preferred model, we examined the improvement in model deviance using the likelihood
ratio test (Δ deviance). If a variable was unrelated to the dependent variable and its removal
did not significantly worsen model fit, it was removed in the final model to maximize
parsimony. Additional specifics about models are noted below. Coefficients for the final
preferred models are listed in Tables 2.10.1 and 2.10.2. Complete details on each
taxonomy are provided in the results.
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Model assumptions were evaluated for preferred models; there were mild to
moderate violations of normal residuals and/or homoscedasticity found in each analysis.
However, no remedial action successfully alleviated these problems. Therefore, remedial
actions were not employed, as ML is robust to mild to moderate violations of assumptions.
Data were examined for multivariate outliers, and these observations were replaced as
missing in the data analyzed (n = 5 observations across the entire study). All missing data
were handled using full information maximum likelihood estimations.
In Experiment 2, linear regression was used to analyze total distance traveled (TDT)
during the locomotor activity assessment.
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Table 2.10.1: Preferred model results for acquisition, escalation, and extinction data. The
coefficients for the final preferred models for acquisition, escalation, first hour of
escalation, Experiment 1 extinction, and Experiment 2 extinction are shown below. Cov =
covariance, Var = variance, -2 LL = -2 Log Likelihood, Δ Deviance = delta deviance, I =
intercept, S = slope, Q = quadratic. *(p < .05), **(p < .01), ***(p < .001), and ****(p <
.0001).

Fixed Effects
Initial Status
Intercept
LgA
Female
Session
Intercept
LgA
Female
Session x
Session
Intercept
LgA
Female
Log(session)
Intercept
LgA
Female
Active
Intercept
Female
Active x
Session
Intercept
Female
Random
Effects
L1 Residual
Cov (I,S)
Var (I)
Var (S)
Cov (I, Q)
Cov (S, Q)
Var (Q)
-2 LL

Model
1st-h
Escalation

Exp 1.
Extinction

Exp 2.
Extinction

1.55****
-0.10*
0.040

1.82****
-0.21**
-0.077

-0.40****
0.18***
0.059

-0.68****
0.29****
-0.040

0.0092****
-0.0098*
0.018***
0.012**

0.025****
-0.020*
0.026**
0.025**

-706.5

-295.8

Acquisition

Escalation

3.96****
1.48*
-1.24*

6.90
48.38****
12.54*

11.99****
-0.72
2.69*

-0.47***
-0.29

0.52
5.56****
-0.28

0.33
0.78**
0.11

-0.0048
-0.084
-0.0086

-0.0048
-0.0076
-0.01

0.75
-0.89
1.51****
0.73**
13.58****
-0.072
1.76*
0.011

5404

188.39****
-2.85
458.86****
18.61****
0.12
-0.74****
0.036****
11376.7
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13.45****
-0.37
14.22****
0.86****
0.020
-0.032****
0.0014****
7733.9

Table 2.10.2: Preferred model results for reinstatement data. The coefficients for the final
preferred models for fentanyl-, yohimbine-, and cue-induced reinstatement are shown
below. Vehicle is the reference category for the fentanyl and yohimbine models. The last
extinction session is the reference category for the cue model. Cov = covariance, Var =
variance, -2 LL = -2 Log Likelihood, I = intercept. *(p < .05), **(p < .01), ***(p < .001),
and ****(p < .0001).
Fixed Effects
Fentanyl
Initial Status
Intercept
7.39*
LgA
7.19
Female
13.25**
LgA x Female
-10.06
Fent 10 ug/kg
Intercept
13.09****
Fent 30 ug/kg
Intercept
9.86*
LgA
13.06*
Female
9.37
LgA x Female
-13.69
Yoh 1 mg/kg
Intercept
Yoh 2 mg/kg
Intercept
Cue
Intercept
LgA
Female
LgA x Female
Random Effects
L1 Residual
81.81****
Var (I)
48.48**
-2 LL
727.9
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Model
Yohimbine
15.09****

Cue
10.80****
2.42
-4.18

8.34***
4.09
29.60****
4.58
2.42
-20.18**
71.33****
59.72**
722.3

75.99****
12.59
482.6

CHAPTER 3. RESULTS
3.1

Experiments 1 and 2: Acquisition
Data from Experiments 1 and 2 were combined for analysis of the acquisition phase

during autoshaped training (Fig. 3.1.1). Active lever pressing increased significantly more
over time than inactive lever pressing for both males (difference in change = 1.51, p < .001)
and females (difference in change = 2.24, p < .001), indicating that all animals acquired
fentanyl self-administration. However, acquisition was more pronounced for females, as
the difference between active and inactive lever pressing was greater for females than
males across sessions (a lever x session x sex interaction, 0.73, p < .01). There was no sex
difference in change in inactive lever pressing (male change = -0.48, female change = 0.77, p > .05), but females increased active lever pressing more rapidly (female change =
1.47, p < .001) than males (male change = 1.03, p < .001); difference in change = .44, p <
.01. On session 1, females (M = 5.44) pressed the inactive lever more than the males (M =
3.96); difference in means = 1.48 p < .05. There was no difference in active lever pressing
between males (M = 4.71) and females (M = 5.30) on session 1 (p > .05). Subjects in Cohort
5 engaged in less lever pressing than other cohorts (1.24, p < .05). Details of the analysis
are provided in Table 3.1.1 and Figure 3.1.2.
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Female Active *
Female Inactive
Male Active *
Male Inactive

Lever Presses

25
20

^
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+
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0
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4

Session
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6
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Figure 3.1.1: Acquisition during the autoshaping procedure collapsed across Experiments
1 and 2. Mean (±SEM) number of active and inactive lever presses for females and males
across 1-hr sessions. The difference between active and inactive lever change was
significant for both males and females *(both p < .001). The difference between the active
and inactive lever change across session was greater in females than males ^(p < 0.01).
Females showed higher inactive lever presses on session 1 than males +(p < .05).
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Table 3.1.1: Model results for acquisition collapsed across Experiments 1 and 2. The
coefficients from all models performed in the initial acquisition analysis are shown below.
Model C was chosen as the preferred model, considering it provided the last significant
increase in delta deviance. Model C included initial status, session, active, and active x
session as level-1 variables, and included female as a level-2 variable. Cov = covariance,
Var = variance, -2 LL = -2 Log Likelihood, Δ Deviance = delta deviance, I = intercept, and
S = slope. *(p < .05), **(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial Status
Intercept
Female
Cohort 5
Session
Intercept
Female
Active
Intercept
Female
Active x
Intercept
Female
Random
L1 Residual
Cov (I,S)
Var (I)
Var (S)
-2 LL
Δ Deviance

UMM

UGM

Model
Model A

Model B

Model C

5.61****

4.66****

4.88****

4.74****

-1.27*

-1.28*

3.96****
1.48*
-1.24*

0.32***

-0.63****

-0.47***
-0.29

0.29

0.75
-0.89

1.89****

1.51****
0.73**

13.80****
-0.024
2.19**
0a
5432.1
617.6****

13.58****
-0.072
1.76*
0.011
5404
28.1****

0.31***

27.64****
1.28*
6069.2

27.22****
-0.11
2.00
0a
6054.8
14.4***

27.22****
-0.058
1.42
0a
6049.7
5.1*
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𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒚𝒚 = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺) + 𝝅𝝅𝟐𝟐𝟐𝟐 (𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨 𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳) +
𝝅𝝅𝟑𝟑𝟑𝟑 (𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨 𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝒙𝒙 𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺) + 𝜺𝜺𝒊𝒊𝒊𝒊

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪 𝟓𝟓) + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏 + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟏𝟏𝟏𝟏
𝝅𝝅𝟐𝟐𝟐𝟐 = 𝜸𝜸𝟐𝟐𝟐𝟐 + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭)
𝝅𝝅𝟑𝟑𝟑𝟑 = 𝜸𝜸𝟑𝟑𝟑𝟑 + 𝜸𝜸𝟑𝟑𝟑𝟑 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭)

Figure 3.1.2: Preferred model for acquisition collapsed across Experiments 1 and 2. The
final equation for Model C for acquisition collapsed across Experiments 1 and 2 is depicted
above.
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3.2

Experiments 1 and 2: Escalation
Data from Experiments 1 and 2 were combined for analysis of the escalation phase.

Two sets of analyses were conducted for escalation. Both sets of analyses followed the
general form described in the data analysis section. The first set included data from the full
session for each subject (1-h for ShA group and 6-h for LgA group; Fig. 3.2.1.1). The
second set accounted for the different lengths of time between the two access groups by
only analyzing the first hour of data from the LgA group (1-h of data from each access
group per session; Fig. 3.2.2.1).
3.2.1

Results of Model Using Complete Data

The preferred model included a quadratic term, indicating that the change in active
lever pressing followed a curvilinear trajectory for some subjects (LgA rats reach a point
where their lever pressing levels off). There was no significant change in active lever
pressing across sessions for ShA rats (change = 0.38, p > .05). However, active lever
pressing significantly increased across sessions for LgA rats (change = 5.94, p < .001),
indicating escalation for LgA rats. The model also included an interaction between access
group and change in active lever pressing across sessions, indicating that the change in
active lever pressing across sessions was greater for LgA rats (difference in change = 5.56,
p < 001). Females (M = 43.63) pressed the active lever significantly more than males (M =
31.09); difference in means = 12.54, p < .05. LgA rats (M = 61.55) also had greater active
lever pressing on session 1 than ShA rats (M = 13.17); difference in means = 48.38, p <
0.01. Details of the analysis are provided in Table 3.2.1.1 and Figure 3.2.1.2.
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Figure 3.2.1.1: Escalation collapsed across Experiments 1 and 2 using all data. Mean
(±SEM) number of active lever presses for ShA and LgA females and males across
sessions. The LgA group pressed the active lever more on session 1 than the ShA group
#(p < .001). Females had more active lever presses than males ^(p < .05). LgA rats
escalated intake across sessions *(p < .001), but ShA rats did not (p > .05).
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Table 3.2.1.1: Model results for escalation collapsed across Experiments 1 and 2 using all
data. The coefficients from all models performed in the initial escalation analysis are shown
below. Model B was the preferred model, considering it was the final model to show an
increase in the delta deviance. Cov = covariance, Var = variance, -2 LL = -2 Log
Likelihood, Δ Deviance = delta deviance, I = intercept, S = slope, and Q = quadratic. *(p
< .05), **(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial Status
Intercept
LgA
Female
LgA x Female
Slope
Intercept

Model
Quadratic
Model A

UMM

UGM

62.41****

41.39****

38.02****

2.13****

3.18****

LgA
Female
LgA x Female
Quadratic
Intercept
LgA
Female
LgA x Female
Random
Effects
L1 Residual
Cov (I,S)
Var (I)
Var (S)
Cov (I, Q)
Cov (S, Q)

-0.053*

678.16****

231.85****

188.41****

3089.68***
*

53.58****
1327.03***
*
7.23****

64.11**
1086.52***
*
26.24****
-0.94
0.8501****
0.03704***
*
11463.2
155.1****

Var (Q)
-2 LL
Δ Deviance

12850.4

11618.3
1232.1****
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Model B

Model C

13.35**
48.56****

6.90
48.38****
12.54*

11.945*
38.29****
2.72
19.34

0.37
5.5574***
*

0.52
5.5634***
*
-0.2771

0.35

-0.0092
-0.084

-0.0048
-0.084
-0.0086

-0.0071
-0.079
-0.0042
-0.0094

188.37***
*
-3.75
498.33***
*
18.66****
0.097
-0.74****

188.39***
*
-2.85
458.86***
*
18.61****
0.12
-0.74****

188.41***
*
-2.058
435.05***
*
18.57****
0.12
-0.74****

0.036****

0.036****

0.036****

11382.4
80.8****

11376.7
5.7*

11372.9
3.8

5.90***
0.050
-0.65

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒚𝒚 = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (Session) + 𝝅𝝅𝟐𝟐𝟐𝟐 (𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺 𝒙𝒙 𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺) + 𝜺𝜺𝒊𝒊𝒊𝒊
𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏 + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟏𝟏𝟏𝟏

𝝅𝝅𝟐𝟐𝟐𝟐 = 𝜸𝜸𝟐𝟐𝟐𝟐 + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟐𝟐𝟐𝟐
Figure 3.2.1.2: Preferred model for escalation collapsed across Experiments 1 and 2 using
all data. The final equation for Model B for escalation collapsed across Experiments 1 and
2 using all data is depicted above.
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3.2.2

Results of Model Using Only First Hour of Data Per Session

Results are similar to those of the prior set of analyses. The preferred model
included a quadratic term, indicating that change in active lever pressing followed a
curvilinear trajectory for some rats (female LgA rats reach a point where their lever
pressing levels off). There was no significant change in active lever pressing across
sessions for ShA rats (change = 0.39, p > .05). However, active lever pressing significantly
increased over time for LgA rats (change = 1.17, p < .001), indicating escalation for LgA
rats. The model also included an interaction between access group and change in active
lever pressing across sessions, suggesting that the change in active lever pressing across
sessions was greater for LgA rats (difference in change = 0.78, p < .01). Females (M =
14.32) pressed the active lever significantly more than males (M = 11.63); difference in
means = 2.69, p < .05. Details of the analysis are provided in Table 3.2.2.1 and Figure
3.2.2.2.
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Figure 3.2.2.1: Escalation collapsed across Experiments 1 and 2 using the first hour of each
session. Mean (±SEM) number of active lever presses for ShA and LgA females and males
across sessions. Females had more active lever presses than males ^(p < .05). LgA rats
escalated intake across session *(p < .001), but ShA rats did not (p > .05).
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Table 3.2.2.1: Model results for escalation collapsed across Experiments 1 and 2 using the
first hour of each session. The coefficients from all models performed in the initial first
hour of escalation analysis are shown below. The taxonomy for the first hour of escalation
is analogous to the escalation taxonomy. Cov = covariance, Var = variance, -2 LL = -2 Log
Likelihood, Δ Deviance = delta deviance, I = intercept, S = slope, and Q = quadratic. *(p
< .05), **(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial Status
Intercept
LgA
Female
LgA x Female
Slope

UMM

UGM

Quadratic

Model
Model A

18.90*
***

13.92*
***

13.028****

0.51**
**

0.78****

Intercept
LgA
Female
LgA x Female
Quadratic
Intercept
LgA
Female
LgA x Female
Random Effects
L1 Residual
Cov (I,S)
Var (I)

34.50*
***
47.95*
***

Var (S)
Cov (I, Q)
Cov (S, Q)
Var (Q)
-2 LL
Δ Deviance

8785

15.30*
***
0.15
19.79*
***
0.26**
**

7866.2
918.8*
***

Model B

Model C

13.38****

11.99****

11.96****

-0.69

-0.72
2.69*

-0.67
2.75
-0.12

0.38*

0.33

0.35

0.79**

0.78**
0.11

0.75*
0.074
0.066

-0.014*

-0.0099
-0.0079

-0.0048
-0.0076
-0.010

-0.0070
-0.0029
-0.0056
-0.0090

13.44****

13.44****

13.45****

13.44****

-0.37

-0.30

-0.37

-0.37

15.93****

16.02****

14.22****

14.21****

1.00****

0.86****

0.86****

0.86****

0.012
-0.033****
0.0014****
7774

0.014
-0.032****
0.0015****
7743.6

0.020
-0.032****
0.0014****
7733.9

0.020
-0.032****
0.0014****
7733.3

92.2****

30.4****

9.7*

0.6
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𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒚𝒚 = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (Session) + 𝝅𝝅𝟐𝟐𝟐𝟐 (𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺 𝒙𝒙 𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺) + 𝜺𝜺𝒊𝒊𝒊𝒊
𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏 + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟏𝟏𝟏𝟏

𝝅𝝅𝟐𝟐𝟐𝟐 = 𝜸𝜸𝟐𝟐𝟐𝟐 + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟐𝟐𝟐𝟐
Figure 3.2.2.2: Preferred model for escalation collapsed across Experiments 1 and 2 using
the first hour of each session. The final equation for Model B for escalation collapsed across
Experiments 1 and 2 using the first hour of each session is depicted above.
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3.3

Experiments 1 and 2: Extinction
Since extinction conditions differed between Experiments 1 and 2, separate

analyses were conducted for each experiment. For Experiment 1 (Fig. 3.3.1), there was an
effect of access group on session 1 active lever pressing and change in active lever pressing
across sessions. LgA rats (M = 1.46) engaged in less log(active lever presses) than ShA
rats (M = 1.57) during session 1; difference in means = -0.10, p ≤ .05. LgA rats exhibited
less decay in responding (change = -0.19, p < .001) than ShA rats (change = -0.37, p <
.001); difference in change = .18, p < .001. Details of the analysis are provided in Table
3.3.1 and Figure 3.3.2.
For Experiment 2 (Fig. 3.3.3), results were similar. There was an effect of access
group on session 1 active lever pressing and change in active lever pressing across sessions.
LgA rats (M = 1.57) engaged in less log(active lever presses) than ShA rats (M = 1.78, p <
.0001) during session 1; difference in means = -.21, p = < .01. LgA rats also exhibited less
decay in responding (change = -0.41, p < .001) than ShA rats (change = -0.70, p < .001);
difference in change = 0.29, p < .0001. Details of the analysis are provided in Table 3.3.2
and Figure 3.3.4.
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Figure 3.3.1: Extinction in Experiment 1 with cue light maintained. Mean (±SEM) number
of active lever presses for ShA and LgA females and males across sessions. LgA rats
pressed the active lever less than ShA rats on session 1 ^(p < .05). The LgA group showed
less decay of active lever pressing than the ShA group *(p < .001).
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Table 3.3.1: Model results for extinction in Experiment 1 with cue light maintained. The
coefficients from all models performed in the initial Experiment 1 extinction analysis are
shown below. Model B was the preferred model. Cov = covariance, Var = variance, -2 LL
= -2 Log Likelihood, Δ Deviance = delta deviance, I = intercept, and S = slope. *(p < .05),
**(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial Status
Intercept
LgA
Female
LgA x Female
Log(Session)
Intercept
LgA
Female
LgA x Female
Random
Effects
L1 Residual
Cov (I,S)
Var (I)
Var (S)
-2 LL
Δ Deviance

Model
Model A

UCM

UCG

1.30****

1.52****

-0.28****

Model B

Model C

1.57****
-0.10

1.55****
-0.10*
0.040

1.54****
-0.086
0.058
-0.035

-0.37****
0.18***

-0.40****
0.18***
0.059

-0.42****
0.23***
0.11
-0.095

0.020**** 0.0092**** 0.0092**** 0.0092**** 0.0092****
-0.014*
-0.0092*
-0.0098*
-0.010*
0.011***
0.021***
0.018***
0.018***
0.018***
0.021**
0.013**
0.012**
0.011**
-403.5
-688.5
-700
-706.5
-710.1
****285
**11.5
*6.5
3.6
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𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒍𝒍𝒍𝒍𝒍𝒍(𝒚𝒚) = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (Log(Session)) + 𝜺𝜺𝒊𝒊𝒊𝒊

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏 + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟏𝟏𝟏𝟏

Figure 3.3.2: Preferred model for extinction in Experiment 1 with cue light maintained.
The final equation for Model B for extinction in Experiment 1 with cue light maintained is
depicted above.
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Figure 3.3.3: Extinction in Experiment 2 with cue light omitted. Mean (±SEM) number of
active lever presses for ShA and LgA females and males across sessions. ShA animals
pressed the active lever more than LgA animals ^(p < .05). The LgA group showed less
decay of active lever pressing than the ShA group *(p < .001).
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Table 3.3.2: Model results for extinction in Experiment 2 with cue light omitted. The
coefficients from all models performed in the initial Experiment 2 extinction analysis are
shown below. Model B was the preferred model, considering it was the last to have a
significant increase in delta deviance score. Cov = covariance, Var = variance, -2 LL = -2
Log Likelihood, Δ Deviance = delta deviance, I = intercept, and S = slope. *(p < .05), **(p
< .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial status
Intercept
LgA
Female
LgA x Female
Log(Session)
Intercept
LgA
Female
LgA x Female
Random
Effects
L1 Residual
Cov (I,S)
Var (I)
Var (S)
-2 LL
Δ Deviance

UCM

UCG

1.23****

1.67****

-0.57****

Model
Model A

Model B

Model C

1.78****
-0.22**

1.82****
-0.21**
-0.077

1.77****
-0.12
0.0098
-0.18

-0.71****
0.29****

-0.68****
0.29****
-0.040

-0.68****
0.29**
-0.040
0.0011

0.067**** 0.025**** 0.025**** 0.025**** 0.025****
-0.035**
-0.019*
-0.020*
-0.020*
0.011**
0.040***
0.028**
0.026**
0.024**
0.046**
0.025**
0.025**
0.025**
97.8
-275.6
-288.7
-295.8
-301.4
****373.4 ***13.1
*7.1
5.6
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𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒍𝒍𝒍𝒍𝒍𝒍(𝒚𝒚) = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (Log(Session)) + 𝜺𝜺𝒊𝒊𝒊𝒊

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏 + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟏𝟏𝟏𝟏

Figure 3.3.4: Preferred model for extinction in Experiment 2 with cue light omitted. The
final equation for Model B for extinction in Experiment 2 with cue light omitted is depicted
above.
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3.4

Experiment 1: Fentanyl-induced Reinstatement
As shown in Fig. 3.4.1, results indicated that active lever pressing was greater after

10 µg/kg fentanyl (M = 28.19) compared to vehicle (M = 15.10); mean difference = 13.09,
p < .001, indicating reinstatement for all rats at this dose. There was also an interaction
between access group and the effect of 30 µg/kg fentanyl (13.06, p < .05). ShA rats
exhibited greater active lever pressing after 30 µg/kg fentanyl than after vehicle (difference
= 14.55, p < .05), indicating reinstatement. However, the difference between 30 µg/kg
fentanyl and vehicle active lever responding was even larger in LgA rats (difference =
20.77, p < .001), indicating greater reinstatement for the LgA group. Regardless of access
group, females exhibited greater active lever pressing than males (difference in means =
8.22, p < 0.05); there was no significant difference in females based on metestrus/diestrus
vs proestrus vs estrus phases (results not shown).
The analysis of data in Fig. 3.4.1 indicated a near significant interaction between
access group, sex, and the effect of 30 µg/kg fentanyl, -13.68, p = .085. Given the small
sample size, this 3-way interaction was probed. The difference between 30 µg/kg fentanyl
and vehicle was significantly greater for LgA males (difference in means = 22.92, p < .001)
than ShA males (difference in means = 9.86, p < .05), with the difference in differences =
13.06, p < .05. In contrast, the difference between 30 µg/kg fentanyl and vehicle was the
same for LgA females (difference in means = 18.61, p < .001) and ShA females (difference
in means = 19.23, p < .001), with the difference in differences = 0.63, p > .05; there was
no significant difference in females based on metestrus/diestrus vs proestrus vs estrus
phases (results not shown). Thus, based on this exploratory analysis, the effect of 30 µg/kg
fentanyl was moderated by access group only for males. Details of the analysis are provided
in Table 3.4.1 and Figure 3.4.2.
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Figure 3.4.1: Fentanyl-induced reinstatement in Experiment 1. Mean (±SEM) number of
active lever presses for ShA and LgA females and males following vehicle, 10 ug/kg
fentanyl, and 30 ug/kg fentanyl. All rats reinstated to 10 ug/kg and 30 ug/kg fentanyl in
comparison to vehicle *(p < .05). The difference between vehicle and 30 ug/kg fentanyl
responding was greater for the LgA group ^(p < .05). Females had higher active lever
responding than males overall +(p < .01). LgA males reinstated more than ShA males at
the 30 ug/kg fentanyl dose (p < .05).
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Table 3.4.1: Model results for fentanyl-induced reinstatement in Experiment 1. The
coefficients from all models performed in the initial fentanyl-induced reinstatement
analysis are shown below. Model E was chosen as the preferred model, considering it was
the most parsimonious model and did not increase in delta deviance from the previous
model with a significant delta deviance. This model did not include any level-2 predictors
for 10 ug/kg fentanyl, since previously all level-2 predictors were non-significant. Vehicle
responding served as the reference category. Fent = fentanyl, Cov = covariance, Var =
variance, -2 LL = -2 Log Likelihood, Δ Deviance = delta deviance, and I = intercept. *(p
< .05), **(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
UCM
Initial Status
Intercept
25.34****
LgA
Female
LgA x Female
Fent 10 ug/kg
Intercept
LgA
Female
LgA x Female
Fent 30 ug/kg
Intercept
LgA
Female
LgA x Female
Random
Effects
L1 Residual
173.47****
Var (I)
56.30*
-2 LL
789.2
Δ Deviance

Model A

Model
Model B
Model C

15.09**** 14.81****
0.56

13.09****

11.50***
3.19

17.66**** 13.75****
7.81

Model D

Model E

11.78**
0.56
6.06

10.13*
3.88
9.38
-6.63

7.39*
7.19
13.25**
-10.06

9.34*
3.19
0.35

7.63
6.63
7.75
-6.88

13.094****

11.41**
7.81
4.69

7.13
16.38*
13.25*
-17.13

9.86*
13.06*
9.37
-13.69

89.47**** 85.61**** 83.91**** 79.27****
84.30**
81.11**
61.15**
49.33**
746.8
742.7
734.8
725.9
****42.4
4.1
*7.9
*8.9

54

81.81****
48.48**
727.9
2

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒚𝒚 = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (10 ug/kg Fentanyl) + 𝝅𝝅𝟐𝟐𝟐𝟐 (𝟑𝟑𝟑𝟑 𝒖𝒖𝒖𝒖/𝒌𝒌𝒌𝒌 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜺𝜺𝒊𝒊𝒊𝒊

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳 𝒙𝒙 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏

𝝅𝝅𝟐𝟐𝟐𝟐 = 𝜸𝜸𝟐𝟐𝟐𝟐 + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜸𝜸𝟐𝟐𝟐𝟐 (𝑳𝑳𝑳𝑳𝑳𝑳 𝒙𝒙 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭)
Figure 3.4.2: Preferred model for fentanyl-induced reinstatement in Experiment 1. The
final equation for Model E for fentanyl-induced reinstatement in Experiment 1 is depicted
above.
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3.5

Experiment 1: Yohimbine-induced Reinstatement
The preferred model included only the dummy variables for 1 and 2 mg/kg

yohimbine as predictors of active lever pressing. Sex, access group, and interactions
between sex and access group did not improve model fit and were not significant predictors
of active lever pressing. As shown in Fig. 3.5.1, active lever pressing was greater after 1
mg/kg yohimbine (M = 23.43, p < .001) compared to vehicle (M = 15.09, p < .0001);
difference in means = 8.34, p < .001, indicating that rats reinstated at this yohimbine dose.
Active lever pressing was marginally greater following 2 mg/kg yohimbine group (M =
19.18, p < .001) compared to vehicle (M = 15.09, p < .0001); difference in means = 4.09,
p = .06. Details of the analysis are provided in Table 3.5.1 and Figure 3.5.2.
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Figure 3.5.1: Yohimbine-induced reinstatement in Experiment 1. Mean (±SEM) number
of active lever presses for ShA and LgA females and males following vehicle, 1 mg/kg
yohimbine, and 2 mg/kg yohimbine. The 1 mg/kg yohimbine dose produced reinstatement
in comparison to vehicle, collapsed across access group and sex *(p < .001).
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Table 3.5.1: Model results for yohimbine-induced reinstatement in Experiment 1. The
coefficients from all models performed in the initial yohimbine-induced reinstatement
analysis are shown below. Model A was the preferred model, because adding each level-2
predictor in the following models did not significantly increase the delta deviance. Vehicle
responding served as the reference category. Yoh = yohimbine, Cov = covariance, Var =
variance, -2 LL = -2 Log Likelihood, Δ Deviance = delta deviance, and I = intercept. *(p
< .05), **(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial Status
Intercept
LgA
Female
LgA x female
Yoh 1 mg/kg
Intercept
LgA
Female
LgA x Female
Yoh 2 mg/kg
Intercept
LgA
Female
LgA x Female
Random
Effects
L1 Residual
Var (I)
-2 LL
Δ Deviance

UCM

Model A

Model
Model B

Model C

Model D

19.24**** 15.09**** 14.81****
0.56

11.78**
0.56
6.06

10.125**
3.88
9.37
-6.63

8.34***

9.13**
-1.56

8.22*
-1.56
0.66

5.13
4.63
8
-12.38

4.09

3.25
1.69

1.41
1.69
3.69

0.25
4
6
-4.63

88.74**** 71.33**** 70.67**** 69.82**** 67.38****
53.92**
59.72**
59.85**
44.55**
32.92**
736.3
722.3
721.7
714.3
707.2
****14.0
0.6
7.4
7.1
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𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒚𝒚 = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (1 mg/kg Yohimbine) + 𝝅𝝅𝟐𝟐𝟐𝟐 (𝟐𝟐 𝒎𝒎𝒎𝒎/𝒌𝒌𝒌𝒌 𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀𝒀) + 𝜺𝜺𝒊𝒊𝒊𝒊
𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜻𝜻𝟎𝟎𝟎𝟎
𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏
𝝅𝝅𝟐𝟐𝟐𝟐 = 𝜸𝜸𝟐𝟐𝟐𝟐
Figure 3.5.2: Preferred model for yohimbine-induced reinstatement in Experiment 1. The
final equation for Model A for yohimbine-induced reinstatement in Experiment 1 is
depicted above
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3.6

Experiment 2: Cue-induced Reinstatement
As shown in Fig. 3.6.1, there was a 3-way interaction between cue condition, sex,

and access group, -20.18, p < .01. All groups exhibited cue-induced reinstatement. Cueinduced reinstatement in LgA females (difference between cue and extinction = 16.42, p <
.0001) was significantly less than in ShA females (difference between cue and extinction
= 32.02, p < .0001); difference in reinstatement = 15.60, p < .01. However, cue-induced
reinstatement in LgA males (difference between cue and extinction = 34.17, p < .0001)
was not significantly different from ShA males (difference between cue and extinction =
29.60, p < .0001); difference in reinstatement = 4.58, p > .05. Thus, the effect of access
group on cue-induced reinstatement was only observed for females; there was no
significant difference in females based on metestrus/diestrus vs proestrus vs estrus phases
(results not shown).
Additional probing of the 3-way interaction examined how sex differences varied
across the access groups. Cue-induced reinstatement for LgA males (difference between
cue and extinction = 34.17, p < .0001) was significantly greater than LgA females
(difference between cue and extinction = 16.42, p < .0001); difference in reinstatement =
17.75, p < .01. However, cue-induced reinstatement for ShA males (difference between
cue and extinction = 29.60, p < .0001) was not significantly different from ShA females
(difference between cue and extinction = 32.02, p < .0001); difference in reinstatement =
2.43, p > .05. Thus, a sex difference was only observed for LgA rats. Details of the analysis
are provided in Table 3.6.1 and Figure 3.6.2.
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Figure 3.6.1: Cue-induced reinstatement in Experiment 2. Mean (±SEM) number of active
lever presses for ShA and LgA females and males following the final extinction session
(Ext) or cue-induced reinstatement (Cue). All rats reinstated to the cue in comparison to
their final extinction session *(p < .001). There was also a significant cue x access group x
sex interaction, indicating the difference between the final extinction session between
access groups was moderated by sex, with LgA females showing less reinstatement than
LgA males #(p < .01).
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Table 3.6.1: Model results for cue-induced reinstatement in Experiment 2. The coefficients
from all models performed in the initial cue-induced reinstatement analysis are shown
below. Model D was chosen as the final preferred model because it maximized parsimony
and did not have a delta deviance higher than the previous model with a significant delta
deviance. Last extinction session responding served as the reference category. Cov =
covariance, Var = variance, -2 LL = -2 Log Likelihood, Δ Deviance = delta deviance, and
I = intercept. *(p < .05), **(p < .01), ***(p < .001), and ****(p < .0001).
Fixed Effects
Initial Status
Intercept
LgA
Female
LgA x Female
Cue
Intercept
LgA
Female
LgA x Female
Random
Effects
L1 Residual
Var (I)
-2 LL
Δ Deviance

UMM

Model A

23.52****

9.70****

Model
Model B
8.59**
2.29

Model C

Model D

9.75**
4.68
-2.19
-4.12

10.80****
2.43
-4.18

27.64**** 30.88**** 30.50**** 29.60****
-6.69
2.64
4.58
0.72
2.43
-16.64
-20.18**
314.40**** 96.36**** 90.76**** 75.61**** 75.99****
0a
27.10
29.61
12.44
12.59
566.8
503.5
501.4
482.2
482.6
****63.3
2.1
**19.2
0.4
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𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟏𝟏: 𝒚𝒚 = 𝝅𝝅𝟎𝟎𝟎𝟎 + 𝝅𝝅𝟏𝟏𝟏𝟏 (Cue) + 𝜺𝜺𝒊𝒊𝒊𝒊

𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳𝑳 𝟐𝟐: 𝝅𝝅𝟎𝟎𝟎𝟎 = 𝜸𝜸𝟎𝟎𝟎𝟎 + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟎𝟎𝟎𝟎 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜻𝜻𝟎𝟎𝟎𝟎

𝝅𝝅𝟏𝟏𝟏𝟏 = 𝜸𝜸𝟏𝟏𝟏𝟏 + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑳𝑳𝑳𝑳𝑳𝑳) + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭) + 𝜸𝜸𝟏𝟏𝟏𝟏 (𝑳𝑳𝑳𝑳𝑳𝑳 𝒙𝒙 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭)
Figure 3.6.2: Preferred model for cue-induced reinstatement in Experiment 2. The final
equation for Model D for cue-induced reinstatement in Experiment 2 is depicted above.
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3.7

Experiment 2: Locomotor Activity Following Cue-induced Reinstatement
To assess whether the reduced reinstatement responding of LgA females merely

reflected a general decrease in behavior, the locomotor results on the day following the last
reinstatement test in Experiment 2 are summarized in Fig. 3.7.1. Because only one
observation per rat was available, multiple linear regression of locomotor activity was used
to test hypotheses. Models were similar in form to the cue-induced reinstatement model
described above (sex, access group, and the sex x access group interaction were included
as independent variables). Results indicated a significant sex x access group interaction, B
= 3773.32, p < .001. For males, locomotor activity was greater for LgA rats (M = 6894.78)
than ShA rats (M = 5471.40), B = 1423.38, p < .05. For females, locomotor activity was
less for LgA rats (M = 8601.89) than ShA rats (M = 10952.00), B = 2349.94, p < .001.
Thus, LgA sessions increased locomotor activity for males and decreased locomotor
activity for females. For ShA rats, locomotor activity was greater in females (M =
10952.00) than males (M = 5471.40), B = 5480.43, p < .001. A similar, but smaller effect
was found between LgA females (M = 8601.89) and males (M = 6894.78), B = 1707.11, p
< .01. Thus, females showed greater overall locomotor activity in comparison to males.
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Figure 3.7.1: Locomotor activity 24-h following cue-induced reinstatement test in
Experiment 2. Mean (±SEM) distance traveled ShA and LgA females and males. There
was a significant sex x access group interaction ^(p < .001). LgA females expressed less
activity than ShA females *(p < .001); however, LgA males expressed more activity than
ShA males #(p < .05).

65

CHAPTER 4. DISCUSSION
With the goal of determining if escalation of fentanyl intake and reinstatement of
fentanyl seeking are related in males and females, the current study revealed several key
findings. First, during acquisition using an autoshaping procedure in ShA (1-h) sessions,
females acquired self-administration at a faster rate than males. Second, when switched to
LgA (6-h) sessions, both sexes escalated intake across the 21 sessions. No escalation was
obtained with either sex when rats were maintained on ShA sessions. Females selfadministered more than males, regardless of access length. Third, during the extinction
phase, LgA rats responded less than ShA rats on the first session and they experienced a
slower decay of responding. Fourth, and most importantly, ShA and LgA groups showed
a differential pattern of response to the stimuli used during reinstatement testing (fentanyl,
yohimbine, cue). With drug-primed reinstatement, the difference in responding between
vehicle and 30 µg/kg fentanyl responding was greater in LgA males than ShA males. With
yohimbine, only the lower dose of yohimbine (1 mg/kg) produced reinstatement and no
difference between ShA and LgA groups was observed. With cue-primed reinstatement,
there was a 3-way interaction (cue condition x access group x sex) effect which indicated
that cue-induced reinstatement in LgA females was reduced compared to both LgA males
and ShA females. Thus, while LgA sessions were related to greater drug-primed
reinstatement, particularly in males, LgA sessions were not related to greater reinstatement
induced by either yohimbine or a drug-associated cue.
Evidence indicates that females may be more susceptible than males to the
reinforcing effect of drugs of abuse in both clinical and preclinical settings (Lynch et al.,
2002). In rats, previous studies indicate that females have increased vulnerability to the
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acquisition of cocaine and heroin self-administration, and successfully acquire selfadministration in fewer days than males (Lynch & Carroll, 1999; Carroll et al., 2001;
Carroll et al., 2002). A similar effect is found in other substances of abuse such as nicotine,
methamphetamine, and alcohol (Lynch et al., 2002). Evidence suggests that accelerated
acquisition of drug self-administration in females may be a result of estradiol activity (Hu
et al., 2004; Jackson et al., 2006; Lynch, 2006). Similar to results obtained with cocaine
and heroin, the current results demonstrate that females acquire the self-administration of
fentanyl at a faster rate than males. However, females may also have greater lever-press
sampling behavior early in acquisition to facilitate acquisition, as they also showed greater
responding on the inactive lever than males on the first session.
Although prior research indicates that rats given extended access (6- to12-h) to
drug-reinforced responding will escalate their intake across sessions, much of this work
has been conducted with stimulant drugs. For example, cocaine self-administration in rats
escalates when maintained on 6- and 12-h sessions, but not when maintained on 1- or 3-h
sessions (Wee et al., 2007). LgA females also show a more robust escalation in cocaine
self-administration compared to LgA males (Roth & Carroll, 2004). More recent work has
demonstrated that escalation of intake also occurs with opioid self-administration. Rats
placed on LgA self-administration sessions escalate heroin self-administration across 18
sessions, but not when placed on ShA self-administration sessions (Ahmed et al., 2000).
Furthermore, when rats are placed on LgA fentanyl self-administration sessions, they
escalate their intake across sessions (Wade et al., 2015; Morgan et al., 2002). However,
since those previous studies with fentanyl were with males only, our results extend those
findings to demonstrate both males and females escalate their intake of fentanyl similarly
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when given LgA but not ShA sessions. Moreover, the current results indicate that females
express greater active lever pressing for fentanyl than males during self-administration,
regardless of session length.
It is well known that rats extinguish drug seeking when the emitted behavior does
not lead to drug delivery (McNally, 2014). A few studies have shown that extinction of
self-administration behavior may vary depending on the length of the self-administration
session. For example, one study found that LgA rats extinguished slower than ShA rats
(Lenoir & Ahmed, 2007). Consistent with that report, the current study found that when
extinction was performed with or without previous drug-associated cues, LgA rats showed
a less rapid decay of non-reinforced responding compared ShA rats. Paradoxically,
however, ShA rats showed higher responding than LgA rats on the first extinction session.
This latter result contradicts a previous report that ShA rats show less active lever pressing
than LgA rats early in extinction of lever pressing established with heroin (Ahmed et al.,
2000). While a number of procedural differences exist between studies that prevents a firm
explanation of the discrepant findings, the current results indicate that the transient
“extinction burst” that occurs on the first session of reward omission is greatest in ShA
rats, perhaps because they temporally learn during acquisition to emit all of their responses
within one hour.
Drug-primed reinstatement is a common method of inducing drug seeking
following a period of extinction. Rats that previously self-administered cocaine, nicotine,
alcohol, or heroin all show reinstatement after extinction when the self-administered drug
is reintroduced (De Vries et al., 1998; Feltenstein et al., 2012; Le et al., 1998; Shaham et
al., 1994). While it is known that drug seeking can be achieved following a drug prime,
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little research has examined how extended access can alter this type of reinstatement.
Mantsch et al. (2004) found that rats previously maintained on LgA (7-h) sessions were
more sensitive to cocaine-induced reinstatement than rats previously maintained on ShA
(1-h) sessions. Similarly, more robust heroin-induced reinstatement was found in rats
trained on LgA (6-h) sessions than rats trained on ShA (1-h) sessions (Lenoir & Ahmed,
2006). Consistent with those previous reports, which were in only males, the current results
demonstrate that LgA rats show greater fentanyl-induced reinstatement after fentanyl (30
µg/kg) compared to ShA rats. However, this effect was driven primarily by the difference
in reinstatement between LgA and ShA males, suggesting that the relation between
escalation and drug-primed reinstatement may be specific to males.
Yohimbine has been used in previous research to trigger drug seeking following a
period of extinction (Mantsch et al., 2014; See & Waters, 2011). Yohimbine-induced
reinstatement occurs in rats following self-administration of methamphetamine (Shepard
et al., 2004), cocaine (Feltenstein & See, 2006), alcohol (Lee et al., 2004), and nicotine
(Feltenstein et al., 2012), although fentanyl seeking has not been examined. The current
results indicate that reliable reinstatement occurred with 1 mg/kg yohimbine, but not 2
mg/kg yohimbine. However, this low-dose reinstatement effect did not differ between
access group or sex, which contrasts with drug-primed reinstatement. Importantly, recent
evidence indicates that yohimbine appears to produce anxiety- and stress-like symptoms
that may produce response enhancement that is independent of past drug use (Mantsch et
al., 2016; Chen et al., 2015), thus calling into question its validity as a marker of stressinduced reinstatement.
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In another group of rats (Experiment 2), cue-induced reinstatement was also
assessed. Reintroducing a cue previously associated with drug taking is another wellknown method of producing drug seeking following self-administration of alcohol
(Schroeder et al., 2008), cocaine (Sutton et al., 2000), nicotine (Le Foll et al., 2012), heroin
(Rubio et al., 2019) and methamphetamine (Yan et al., 2007). However, little is known
about cue-induced reinstatement after the escalation of drug taking. One study found no
difference between ShA and LgA adult or adolescent male rats in cue-induced morphine
seeking (Doherty, 2009). Similarly, the current study found no difference between ShA
and LgA males. Interestingly, however, LgA females showed reduced cue-induced
reinstatement compared to either ShA females or LgA males. This may reflect, at least in
part, a generalized decrease in activity, as LgA females also displayed less locomotion than
ShA females when tested in a different context; conversely, LgA males displayed more
locomotion than ShA males. The decrease in both cue-induced reinstatement and
locomotor activity observed in LgA females may involve changes in corticotropinreleasing factor (CRF) systems, as CRF in the reward-relevant ventral tegmental area is
associated with cocaine-associated cue learning (Tovar-Diaz et al., 2018) and sex
differences exist in activation of CRF neurocircuitry (Salvatore et al., 2018). Further work
is needed to determine if escalation of fentanyl intake in females leads to lasting changes
in CRF or other reward-relevant systems underlying cue-induced fentanyl seeking.
In conclusion, the current study provides only limited support for the hypothesis
that escalation of fentanyl intake and reinstatement of drug seeking are related processes
since LgA sessions produced greater reinstatement than ShA session to a drug prime, but
not to either yohimbine or a cue, and the drug prime effect was limited to males. In
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addition, LgA males displayed greater cue-induced reinstatement than LgA females. These
results are consistent with clinical data indicating that males are more reactive to cocaineassociated cues than females (Frick, 2020). In addition, while some human research
indicates that females are more susceptible to craving and relapse (Becker, 2016; Robbins
et al., 1999; Fox et al., 2014; Hitschfeld et al., 2015), other studies support that males have
worse outcomes following treatment, despite predicted advantages (Walitzer & Dearing,
2006). Sex differences also occur in relapse patterns, with males oscillating more quickly
between relapse and abstinence compared to females (Gallop et al., 2007). Further work is
needed to uncover the potential mechanisms involved in the sex-dependent differences in
reinstatement observed here following LgA sessions.
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